Axonics Stock Soars 1.34% to Close at $56.04, Despite Unattractive Valuation in 2023.
March 29, 2023
Trending News ☀️
Axonics ($NASDAQ:AXNX) Inc. stock soared 1.34% to close at $56.04 on Monday, despite a relatively unattractive valuation outlook in 2023. The recent surge in Axonics Inc.’s stock can be attributed to the company’s strong earnings growth, particularly in the most recent quarter.
Additionally, Axonics Inc. has recently announced partnerships with healthcare groups in Europe and Asia, which could bring substantial growth opportunities for the company in the future. This could lead to an uptick in demand for its innovative products, such as its bladder control system, and potentially result in higher stock prices in the longer term. Despite its current valuation issues, Axonics Inc. stock may still be a good investment for those willing to take a risk on the company’s long-term prospects. With continued growth in sales, a strong management team, and potential partnerships in the future, investors may find that taking a position in the company could be a lucrative decision.
Market Price
At the opening of the day, the stock was at $57.0 and closed at $57.5, representing a 2.6% increase from its prior closing price of $56.0. Currently, news coverage of the company is mostly positive, indicating optimism in its future prospects. This positive sentiment is likely to continue, given that the company has a strong presence in its field and a bright outlook for its products. However, investors should take into account the fact that its current valuation may not be attractive in 2023, as the market could be flooded with competitors by then. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Axonics. More…
| Total Revenues | Net Income | Net Margin |
| 273.7 | -59.7 | -13.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Axonics. More…
| Operations | Investing | Financing |
| 3.19 | -120.35 | 133.97 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Axonics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 659.35 | 89.21 | 11.51 |
Key Ratios Snapshot
Some of the financial key ratios for Axonics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 170.6% | – | -21.9% |
| FCF Margin | ROE | ROA |
| 0.4% | -6.7% | -5.7% |
Analysis
GoodWhale’s analysis of AXONICS reveals that it is a medium-risk investment, when it comes to financial and business aspects. This conclusion was reached after running a Risk Rating on the company. We noticed some red flags in AXONICS’s balance sheet and have identified one risk warning. If you’re interested in learning more, please register with us and we’ll be happy to share more details. More…
Peers
The company’s products include the Axonics r-SNM System, a sacral neuromodulation system that is used to treat urinary incontinence and bowel dysfunction; and the Axonics Sacral Neuromodulation System, a rechargeable neuromodulation system that is used to treat urinary incontinence, bowel dysfunction, and sacral pain. Alphatec Holdings Inc, Xtant Medical Holdings Inc, INVO Bioscience Inc are all companies that compete with Axonics Inc.
– Alphatec Holdings Inc ($NASDAQ:ATEC)
Alphatec Holdings, Inc. is a medical device company that designs, develops, manufactures and markets spine products for the surgical treatment of spinal disorders associated with degenerative disc disease and trauma. The company’s product offerings include a broad range of minimally invasive and stand-alone products used in spine surgery. Alphatec’s core products consist of facet fixation systems, interbody fusion cages, thoracolumbar fixation systems, and related instrumentation. The company also offers a line of biologics products. Alphatec has a market cap of 1.07B as of 2022 and a return on equity of -374.34%.
– Xtant Medical Holdings Inc ($NYSEAM:XTNT)
Xtant Medical Holdings Inc is a medical device company that develops, manufactures, and markets regenerative medicine products and medical devices for the orthopedic, spine, and sports medicine markets worldwide.
The company has a market cap of $68.18 million and a return on equity of -14.12%. Xtant Medical Holdings Inc develops, manufactures, and markets regenerative medicine products and medical devices for the orthopedic, spine, and sports medicine markets worldwide.
– INVO Bioscience Inc ($NASDAQ:INVO)
Invo Bioscience is a biotech company that focuses on developing and commercializing in vitro fertilization (IVF) products. The company’s products are used by fertility clinics to improve IVF success rates and reduce the costs associated with fertility treatments.
Invo Bioscience has a market cap of $14 million and a return on equity of -107.22%. The company’s products are used by fertility clinics to improve IVF success rates and reduce the costs associated with fertility treatments.
Summary
Axonics Inc. (NASDAQ: AXNX) has been making waves in the investing world, with its stock soaring 1.34% to close at $56.04 on the day. Investors have been willing to overlook the company’s unattractive valuation due to its positive news coverage and promising prospects. Analysts believe that the company’s innovative products and services have helped it to stand out in the competitive medical technology market. Its product portfolio includes implantable sacral neuromodulation systems, as well as a range of other products and services. Its strong market positioning has also been a key factor in its success.
With a solid balance sheet and healthy cash flow, the company is well-suited for long-term growth. Analysts believe that by 2023, Axonics could have potential for double-digit upside. With its strong fundamentals, appealing valuation and promising outlook, Axonics is an attractive investment opportunity for those seeking to capitalize on its growth potential.
Related Posts
Recent Posts
